诺和诺德（NVO）今日盘中大涨6.56%，成为市场焦点。此次股价异动紧随其重磅减肥药Wegovy 7.2mg高剂量版本获英国药品和保健品监管局（MHRA）批准的消息。
消息面上，英国批准的7.2mg剂量是目前标准最高剂量（2.4mg）的三倍，临床试验显示其减重效果显著：72周后患者平均减重20.7%，三分之一受试者减重超25%。这一突破被视为诺和诺德在GLP-1领域对抗礼来替尔泊肽的关键反击，有望进一步巩固其在全球减重市场的领导地位。
此外，贝伦贝格银行同日将诺和诺德目标价上调至415丹麦克朗，叠加欧股开盘上涨近3%的联动效应，以及Wegovy口服片剂在美国上市初期处方量超预期的数据（前四天开出3071张处方），共同推动了此次股价跃升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.